Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease-Reference-Cited by-同舟云学术

Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease

Published:2020-02-26 Issue:3 Volume:71 Page:808-819
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Kanwal Fasiha¹²^ORCID,Kramer Jennifer R.²³^ORCID,Li Liang⁴^ORCID,Dai Jianliang⁴,Natarajan Yamini¹^ORCID,Yu Xian²³,Asch Steven M.⁵⁶^ORCID,El‐Serag Hashem B.¹²^ORCID

Affiliation:

1. Section of Gastroenterology and Hepatology, Department of Medicine Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center Houston TX

2. Center for Innovations in Quality, Effectiveness and Safety (IQuESt) Michael E. DeBakey Veterans Affairs Medical Center Houston TX

3. Section of Health Services Research, Department of Medicine Baylor College of Medicine Houston TX

4. Department of Biostatistics University of Texas MD Anderson Cancer Center Houston TX

5. Center for Innovation to Implementation (Ci2i) Palo Alto Veterans Affairs Medical Center Palo Alto CA

6. Division of Primary Care and Population Health Stanford University Palo Alto CA

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31014

Reference29 articles.

1. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

2. Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

3. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

4. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease

5. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis

Cited by 203 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies;Metabolism;2024-12

2. Diabetes as a risk factor for MASH progression;Diabetes Research and Clinical Practice;2024-11

3. Natural history and progression of metabolic dysfunction-associated steatotic liver disease;The Lancet Gastroenterology & Hepatology;2024-10

4. Editorial: Cardiometabolic criteria matters in MASLD;Alimentary Pharmacology & Therapeutics;2024-09-03

5. Editorial: Cardiometabolic criteria matters in MASLD—Authors' reply;Alimentary Pharmacology & Therapeutics;2024-09-03